

28-29 October 2021

Program

#malariamelb21
malariainmelbourne@gmail.com
https://www.malariainmelbourne.org.au

Program at a Glance

<u>Day 1</u>

Welcome and Housekeeping 09:50 - 10:00am **Plenary Session 1** 10:00 - 10:30am 10:30 - 12:00pm Session 1: Epidemiology 12:00 - 12:30pm Lunch 12:30 - 1:40pm Session 2: Drug development 1:40 - 2:10pm **Short Talks: Session 1** 2:10 - 2:20pm Poster Briefing 2:20 - 2:30pm Break **Poster Session 1** 2:30 - 3:00pm **Session 3: Emerging technologies** 3:00 - 4:10pm

Day 2

09:50 - 10:00am	Welcome and Housekeeping
10:00 - 10:30am	Plenary Session 2
10:30 - 12:00pm	Session 4: Molecular parasitology
12:00 - 12:30pm	Lunch
12:30 - 1:40pm	Session 5: Immunology
1:40 - 2:10pm	Short Talks: Session 2
2:10 - 2:20pm	Poster Briefing
2:20 - 2:30pm	Break
2:30 - 3:00pm	Poster Session 2
3:00 - 4:10pm	Session 6: Surveillance and elimination
4:10 - 4:20pm	Closing Remarks and Awards

Links

Day 1: Zoom

https://unimelb.zoom.us/j/87480697780?pwd=dEZnRDVNOFNPRnVQNWFDR2xSTFF6UT09 Password: 051312

Or by phone:

Dial (Australia): +61 3 7018 2005 or +61 2 8015 6011 Meeting ID: 874 8069 7780 | Password: 051312

More international numbers available: https://unimelb.zoom.us/u/kfYGkYvWr

Or from a H.323/SIP room system:

Dial:87480697780@zoom.aarnet.edu.au | or SIP:87480697780@zmau.us | or 103.122.166.55 Meeting ID: 87480697780 | Password: 051312

Day 1: Remo poster session

https://live.remo.co/e/mim-poster-session-1

Day 2: Zoom

https://unimelb.zoom.us/j/87571163552?pwd=VHAzR2xTRndQcFNZanovOU5qUmNrUT09 Password: 035276

Or by phone:

Dial (Australia): +61 3 7018 2005 or +61 2 8015 6011 Meeting ID: 875 7116 3552 | Password: 035276

More international numbers available: https://unimelb.zoom.us/u/kcWFSlucHB

Or from a H.323/SIP room system:

Dial:87571163552@zoom.aarnet.edu.au | or SIP:87571163552@zmau.us | or 103.122.166.55 Meeting ID: 87571163552 | Password: 035276

Day 2: Remo poster session

https://live.remo.co/e/mim-poster-session-2

09:50 - 10:00am Acknowledgment of Country

Welcome and Housekeeping

10:00 - 10:30am Plenary Session 1

Sponsored by The Walter and Eliza Hall Institute of Medical Research

Session chair: Lisa Ioannidis

Harnessing liver-resident T cell immunity for protection against malaria

Dr Daniel Fernandez-Ruiz - The Department of Microbiology and Immunology and Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, VIC, Australia

10:30 - 12:00pm Session 1: Epidemiology

Session chairs: Myo Naung and Katherine O'Flaherty

T1 Molecular surveillance to assess the impact of sequential malaria control interventions on the reservoir of *Plasmodium falciparum* in a high-transmission area in northern Ghana

Kathryn Tiedje - The Department of Microbiology and Immunology, Bio21 Institute and Peter Doherty Institute, The University of Melbourne, Melbourne, VIC, Australia

T2 Evaluation of the usefulness of intermittent preventive treatment of malaria in pregnancy with sulfadoxine-pyrimethamine in a context with increased resistance of *Plasmodium falciparum* in Kingasani Hospital, Kinshasa in the Democratic Republic of Congo

Evariste Tshibangu (on behalf of Nadine Kayiba Kalenda) -Research Institute of Health and Society, Catholic University of Louvain, Brussels, Belgium

T3 Unravelling var chaos for malaria surveillance: Linkage of the DBL α tag and var

Mun Hua Tan - The Department of Microbiology and Immunology, Bio21 Institute, The University of Melbourne, Melbourne, VIC, Australia

T4 Mixed effect analysis of factors influencing the use of insecticides treated bed nets among pregnant women in Ghana: Evidence from the 2019 malaria indicator survey

Desmond Klu - Centre for Malaria Research, Institute of Health Research, University of Health and Allied Sciences, Ghana

T5 The role of anti-malarial immunity in the spontaneous clearance of molecular-detectable *Plasmodium* spp. infection

Merryn Roe - Disease Elimination Program, Burnet Institute for Medical Research and Public Health, School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia

12:00 - 12:30pm Lunch

12:30 - 1:40pm Session 2: Drug development

Sponsored by The Anti-malaria Synergy TeamSession chairs: Hanh Nguyen and Charlie Jennison

- T6 Dual plasmepsin-targeting antimalarial agents disrupt multiple stages of the malaria parasite lifecycle
 Paola Favuzza The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia
- T7 An untargeted target identification approach for novel aminobenzimidazole antimalarials identifies Exportin-1 as a potential target

 Matthew Challis Monash Institute of Pharmaceutical Sciences, Drug delivery, disposition and dynamics, Global Health Therapeutic Program Area, Monash University,
- T8 L672H mutation in the *P. falciparum* flavokinase confers resistance to roseoflavin and 8-aminoriboflavin Ayman Hemasa Research School of Biology, Australian National University, Canberra, ACT, Australia

Melbourne, VIC, Australia

T9 The sulfonylpiperazine MMV020291 prevents red blood cell invasion through interference with actin-1/profilin

dynamics in the malaria parasite *Plasmodium* falciparum

Madeline Dans - Burnet Institute, The Walter and Eliza Hall Institute, Melbourne, VIC, Australia and Deakin University, Geelong, VIC, Australia

1:40 - 2:10pm Short Talks: Session 1

Session chairs: Jack Adderley and Kirsty McCann

ST1 Plasmodium falciparum's redox homeostasis is perturbed by peroxide antimalarials

Ghizal Siddiqui - Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, VIC Australia

ST2 Can we target the mosquito stages of *Plasmodium* with 'drugs' to reduce transmission?

Sarah Farrell - School of BioSciences, The University of Melbourne, VIC, Australia

ST3 Molecular surveillance of asymptomatic *Plasmodium* falciparum in high-transmission regions in the context of interventions

Dionne Argyropoulos - The Department of Microbiology and Immunology, Bio21 Institute and Peter Doherty Institute, The University of Melbourne, Melbourne, VIC, Australia

ST4 Effect of primaquine daily dose on tolerability in patients with uncomplicated *Plasmodium vivax*: a systematic review and individual patient data meta-analysis

Megha Rajasekhar - Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, VIC, Australia

ST5 Complement and Fcγ-receptor mediated antibody effector functions target merozoites and are associated with protection from severe malaria in children

Sandra Chishimba - Burnet Institute, Life Sciences and The Department of Medicine at Royal Melbourne Hospital, Melbourne Medical School, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, VIC, Australia

ST6 The *Plasmodium* apicoplast is essential for construction of GPI anchors needed for egress and invasion

Long Kim Huynh - The Department of Biochemistry and Pharmacology, The University of Melbourne, Melbourne, VIC, Australia

ST7 PTEX-mediated export of effector proteins depends upon the length of an unstructured region downstream of the conserved export motif

Mikha Gabriela - Malaria Virulence and Drug Discovery Group, Burnet Institute, Melbourne, VIC, Australia and School of Medicine, Deakin University, Geelong, VIC, Australia

2:10 - 2:20pm Poster Briefing: Coralie Boulet

2:20 - 2:30pm Break

2:30 - 3:00pm Poster Session 1

3:00 - 4:10pm Session 3: Emerging technologies

Session chairs: Dulcie Lautu and Caitlin Bourke

T10 A mathematical model of within-host hypnozoite dynamics for *Plasmodium vivax*

Somya Mehra - School of Mathematics and Statistics, The University of Melbourne, Melbourne, VIC, Australia

T11 Metabolomic and thermal proteomic profiling to facilitate mode of action discovery for multistage active malaria box compounds with unknown targets Carlo Giannangelo - Drug Delivery, Disposition and

Carlo Giannangelo - Drug Delivery, Disposition and Dynamics, Global Health Therapeutic Program Area, Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, VIC, Australia

T12 Investigating the role of the spleen in red blood cell dynamics in malaria using mathematical modelling Saber Dini - Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, VIC, Australia

T13 An interactive, user-friendly platform for end-to-end analysis of targeted amplicon sequencing data

Somesh Mehra - Life Sciences Discipline, Burnet Institute, Melbourne, VIC, Australia

09:50 - 10:00am Acknowledgment of Country

Welcome and Housekeeping

10:00 - 10:30am Plenary Session 2

Sponsored by The Peter Doherty Institute for Infection and Immunity

Session chair: Lee Yeoh

The evolving economic case for malaria control and elimination

Dr Angela Devine - Menzies School of Health Research, Darwin, NT, Australia

10:30 - 12:00pm Session 4: Molecular parasitology

Sponsored by Qiagen

Session chairs: Elyse Dunn and Oliver Looker

T14 Malaria parasite trafficking defect: weird knobs, vesicle pile-up and failure to deliver a critical virulence factor Olivia Maria Silva Carmo - The Department of Biochemistry Pharmacology, Bio21 Molecular Science and and Biotechnology Institute. University of Melbourne. Melbourne, VIC, Australia

T15 Apicoplast derived isoprenoids are essential for the biosynthesis of glycophosphatidylinositol anchors and egress of asexual stage *Plasmodium falciparum*Michaela Bulloch - Department of Biochemistry and Pharmacology, The University of Melbourne, Melbourne, VIC, Australia

T16 Phenotyping the protein kinase CLK3 knockout in Plasmodium parasite

Ying Yui Grace Law - School of Biosciences, The University of Melbourne, VIC, Melbourne, Australia

T17 Knockdown of PTEX impairs the haemoglobin digestion pathway in *Plasmodium falciparum*

Thorey Jonsdottir - Burnet Institute and The Department of Microbiology and Immunology, The University of Melbourne, Melbourne, VIC, Australia

T18 Role of PHIST protein in knob formation

Mohini Anjna Shibu - The Department of Biochemistry and Molecular Biology, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Melbourne, Melbourne, VIC, Australia

12:00 - 12:30pm Lunch

12:30 - 1:40pm Session 5: Immunology

Sponsored by The Burnet Institute

Session chairs: Lynette Beattie and Rhea Longley

T19 Antibody targets and properties for complement fixation against the circumsporozoite protein in malaria immunity

Liriye Kurtovic - Burnet Institute and The Department of Immunology and Pathology, Monash University, Melbourne, VIC. Australia

T20 The role of an innate-like T cell subset during Plasmodium sporozoite infection

Phoebe Dewar - The Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, VIC, Australia

T21 Defining the mechanisms of action of antibodies against *Plasmodium vivax* malaria

Kaitlin Pekin - Burnet Institute, The Department of Microbiology, Monash University, Melbourne, VIC, Australia

T22 Effect of the PAMVAC vaccine on the antibody functional responses in non-pregnant populations

Amaya Ortega - Department of Infectious Diseases, University of Melbourne, The Doherty Institute, Melbourne, VIC, Australia

1:40 - 2:10pm Short Talks: Session 2

Chairs: Emma McHugh and Maria Nogueira De Menezes

ST8 Identification of biochemical changes in drug-resistant Plasmodium falciparum parasites, with a focus on parasite haemoglobin digestion and redox homeostasis

Yunyang Zhou - Monash Institute of Pharmaceutical Sciences, Drug Delivery, Disposition and Dynamics, Melbourne, VIC, Australia

ST9 Untargeted metabolomics analysis reveals cyclopropyl amide antimalarials act by disrupting *Plasmodium falciparum* pyrimidine metabolism

Abbey McCorquodale - Drug Delivery, Disposition and Dynamics, Global Health Therapeutic Program Area, Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, VIC, Australia

ST10 Effect of primaquine dose of the risk of recurrence in patients with uncomplicated *Plasmodium vivax*: a systematic review and individual patient data meta-analysis

Rob Commons - Global Health Division, Menzies School of Health Research and Charles Darwin University, Darwin, NT, Australia, WorldWide Antimalarial Resistance Network (WWARN) and Internal Medical Services, Ballarat Health Services, Ballarat, VIC, Australia

ST11 Identifying key targets for CD8* tissue resident memory T cell based malaria vaccine

Zhengyu (Jeff) Ge - The Department of Microbiology and Immunology, The University of Melbourne, Melbourne, VIC, Australia

ST12 Understanding natural immunity to pre-erythrocytic *P. vivax* proteins in a longitudinal cohort

Kael Schoffer - Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia

ST13 Investigating organellar inheritance of the apicoplast and mitochondrion in *Plasmodium berghei*

Sophie Collier - School of BioSciences, The University of Melbourne, Melbourne, VIC, Australia

ST14 Genomic Profiling of *Plasmodium falciparum* using Targeted Amplicon Sequencing with the Portable MinION-MK1C Sequencer

Zahra Razook - Institute of Mental and Physical Health and Clinical Translation (IMPACT) and School of Medicine, Faculty of Health, Deakin University, Geelong, VIC, Australia and Life Sciences Discipline, Burnet Institute, Melbourne, VIC, Australia

2:10 - 2:20pm Poster Briefing: Coralie Boulet

2:20 - 2:30pm Break

2:30 - 3:00pm Poster Session 2

3:00 - 4:10pm Session 6: Surveillance and elimination

Sponsored by The Australian Centre for Research Excellence in Malaria Elimination (ACREME)

Session chairs: Fiona Agrisano and Charles Narh

T23 Field evaluation of highly sensitive diagnostic methods for detection of malaria infections in pregnancy in Papua New Guinea

Benishar Kombut - Papua New Guinea Institute of Medical Research, Madang, Papua New Guinea and Burnet Institute for Medical Research, Kokopo, Papua New Guinea

T24 Induction, decay, and determinants of functional antibodies induced by the RTS,S malaria vaccine in young children

Gaoqian Feng - Burnet Institute and The Department of Medicine, The University of Melbourne, Melbourne, VIC, Australia

T25 Rebound in the *Plasmodium falciparum* reservoir following the implementation of seasonal malaria chemoprevention and discontinuation of indoor residual spraying

Sanjay Gautam - Department of Microbiology and Immunology, The University of Melbourne, Bio21 Molecular Science and Biotechnology Institute and Peter Doherty Institute, Melbourne, VIC, Australia

T26 Antibody avidity and maintenance in malaria vaccine responses

Jessica Horton - Burnet Institute and The Department of Medicine, University of Melbourne, Melbourne, VIC, Australia

4:10 - 4:20pm Prizes and closing remarks

ST1 Plasmodium falciparum's redox homeostasis is perturbed by peroxide antimalarials

Ghizal Siddiqui - Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, VIC Australia

ST2 Can we target the mosquito stages of *Plasmodium* with 'drugs' to reduce transmission?

Sarah Farrell - School of BioSciences, The University of Melbourne, VIC, Australia

ST3 Molecular surveillance of asymptomatic *Plasmodium* falciparum in high-transmission regions in the context of interventions

Dionne Argyropoulos - The Department of Microbiology and Immunology, Bio21 Institute and Peter Doherty Institute, The University of Melbourne, Melbourne, VIC, Australia

ST4 Effect of primaquine daily dose on tolerability in patients with uncomplicated *Plasmodium vivax*: a systematic review and individual patient data meta-analysis

Megha Rajasekhar - Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, VIC, Australia

ST5 Complement and Fcγ-receptor mediated antibody effector functions target merozoites and are associated with protection from severe malaria in children

Sandra Chishimba - Burnet Institute, Life Sciences and The Department of Medicine at Royal Melbourne Hospital, Melbourne Medical School, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, VIC, Australia

ST6 The *Plasmodium* apicoplast is essential for construction of GPI anchors needed for egress and invasion

Long Kim Huynh - The Department of Biochemistry and Pharmacology, The University of Melbourne, Melbourne, VIC, Australia

ST7 PTEX-mediated export of effector proteins depends upon the length of an unstructured region downstream of the conserved export motif

> Mikha Gabriela - Malaria Virulence and Drug Discovery Group, Burnet Institute, Melbourne, VIC, Australia and School of Medicine, Deakin University, Geelong, VIC, Australia

P1 Application of serological markers for the assessment of the transmission of *Plasmodium vivax* infections in Papua New Guinea

Natalie Cerovac - Population Health and Immunity Division, The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia

- P2 Evaluation of an optimal community-delivered malaria elimination model for the Greater Mekong Sub-region: protocol of a stepped wedge cluster-randomized controlled trial nested with mixed methods studies

 Win Htike Burnet Institute, Melbourne, VIC, Australia
- P3 Understanding the Role of PfMT-A70.2 in the Plasmodium falciparum N6-methyladenosine Writer Complex
 Asela Lakvin Fernando Department of Biochemistry and Molecular Biology, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Melbourne, VIC, Australia
- P4 Perspectives of health and community stakeholders on community-delivered models of malaria elimination in Lao People's Democratic Republic: A qualitative study

 May Chan Oo Burnet Institute Myanmar, Yangon, Myanmar
- P5 The design, synthesis and evaluation of novel metalloaminopeptidase inhibitors as antimalarial agents
 Mahta Mansouri Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Melbourne, VIC, Australia
- P6 N/A
- P7 Repeated *Plasmodium falciparum* infection in humans drives the clonal expansion of an adaptive gamma delta T cell repertoire

Anouk von Borstel - Infection and Immunity Program and The Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Melbourne, VIC, Australia

- P8 A novel mechanism of clindamycin resistance in Plasmodium that does not transmit readily Jessica Home - School of Biosciences, The University of Melbourne, Melbourne, VIC, Australia
- P9 The identification of addiction to a human kinase inhibitor in *Plasmodium falciparum*

Tayla Williamson - Centre for Chronic Infectious and Inflammation Disease, Biomedical Sciences Cluster, School of

- Health and Biomedical Sciences, RMIT University, Melbourne, VIC, Australia
- P10 Identifying the mechanism of action of a novel invasion-blocking compound in *Plasmodium falciparum*Dawson Ling Burnet Institute and The University of Melbourne, Melbourne, VIC, Australia
- P11 Bayesian within-host modelling of red blood cell dynamics and primaquine-induced haemolysis in G6PD deficiency Parinaz Mehdipour Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, VIC, Australia
- P12 Glycosylation of *Plasmodium falciparum* thrombospondin repeats ensures mosquito transmission and sporozoite infectivity

 Justin Boddey The Walter and Eliza Hall Institute of Medical
 - Justin Boddey The Walter and Eliza Hall Institute of Medical Research and The Department of Medical Biology, University of Melbourne, Melbourne, VIC, Australia
- P13 Ultrastructure and function of nuclear microtubules in Plasmodium falciparum gametocytes

 Jiahong Li - Department of Biochemistry and Pharmacology,
 The University of Melbourne, Melbourne, VIC, Australia
- P14 A multiscale mathematical model of *Plasmodium vivax* transmission

Md Nurul Anwar - School of Mathematics and Statistics, The University of Melbourne, Melbourne, VIC, Australia and Department of Mathematics, Bangabandhu Sheikh Mujibur Rahman Science and Technology University, Gopalganj, Bangladesh

ST8 Identification of biochemical changes in drug-resistant *Plasmodium falciparum* parasites, with a focus on parasite haemoglobin digestion and redox homeostasis

Yunyang Zhou - Monash Institute of Pharmaceutical Sciences, Drug Delivery, Disposition and Dynamics, Melbourne, VIC, Australia

ST9 Untargeted metabolomics analysis reveals cyclopropyl amide antimalarials act by disrupting *Plasmodium* falciparum pyrimidine metabolism

Abbey McCorquodale - Drug Delivery, Disposition and Dynamics, Global Health Therapeutic Program Area, Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, VIC, Australia

ST10 Effect of primaquine dose of the risk of recurrence in patients with uncomplicated *Plasmodium vivax*: a systematic review and individual patient data meta-analysis

Rob Commons - Global Health Division, Menzies School of Health Research and Charles Darwin University, Darwin, NT, Australia, WorldWide Antimalarial Resistance Network (WWARN) and Internal Medical Services, Ballarat Health Services, Ballarat, VIC, Australia

ST11 Identifying key targets for CD8* tissue resident memory T cell based malaria vaccine

Zhengyu (Jeff) Ge - The Department of Microbiology and Immunology, The University of Melbourne, Melbourne, VIC, Australia

ST12 Understanding natural immunity to pre-erythrocytic *P. vivax* proteins in a longitudinal cohort

Kael Schoffer - Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia

ST13 Investigating organellar inheritance of the apicoplast and mitochondrion in *Plasmodium berghei*

Sophie Collier - School of BioSciences, The University of Melbourne, Melbourne, VIC, Australia

ST14 Genomic Profiling of *Plasmodium falciparum* using Targeted Amplicon Sequencing with the Portable MinION-MK1C Sequencer

Zahra Razook - Institute of Mental and Physical Health and Clinical Translation (IMPACT) and School of Medicine, Faculty of Health, Deakin University, Geelong, VIC, Australia and Life Sciences Discipline, Burnet Institute, Melbourne, VIC, Australia

P15 N/A

- P16 Optimised sampling of *Plasmodium knowlesi* in Indonesia Lucinda Harrison - School of Mathematics and Statistics, The University of Melbourne, Melbourne, VIC, Australia
- P17 Plasmodium vivax malaria serological exposure markers: assessing the presence and implications of potential cross-reactivity with P. knowlesi
 Rhea Longley Population Health and Immunity Division, WEHI and The Department of Medical Biology, University of
- P18 Alternate synthesis & evaluation of 2 aminobenzimidazole antimalarials

Melbourne, Melbourne, VIC, Australia

Jomo K. Kigotho - Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, VIC, Australia

P19 i-bodies; fully human single domain antibodies are capable of identifying the conserved and conformational epitopes of Apical Membrane Antigen 1 from *Plasmodium falciparum*

Dimuthu Angage - Department of Biochemistry and Genetics, La Trobe Institute for Molecular Sciences, La Trobe University, Melbourne, VIC, Australia

- P20 Sustainability of a mobile phone application-based data reporting system in Myanmar's malaria elimination program: A qualitative study
 - Kaung Myat Thu Burnet Institute Myanmar, Yangon, Myanmar
- P21 Using Anopheles salivary antibody biomarkers to assess the effectiveness of personal insect repellent in Southeast Myanmar

Ellen Kearney - Burnet Institute and Centre for Epidemiology and Biostatistics, The University of Melbourne, Melbourne, VIC. Australia

P22 Investigating the *in vitro* stability profile of bistriazines, a potent novel antimalarial class

Peiyuan Luo - Drug Delivery, Disposition and Dynamics, Global Health Therapeutic Program Area, Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, VIC, Australia

P23 Anti-gametocyte humoral immunity and gametocyte carriage during treatment of uncomplicated falciparum malaria: A multi-national cohort study

Katherine O'Flaherty - Burnet Institute, Melbourne, VIC, Australia

P24 *P. falciparum* tyrosine tRNA synthetase as an antimalarial drug target

Chiawei Tai - Bio21, Department of Biochemistry and Pharmacology, The University of Melbourne, Melbourne, VIC, Australia

P25 Synthesis and biological evaluation of potent *Plasmodium* falciparum M1 & M17 aminopeptidase inhibitors with polar S1' moieties

Petar Calic - Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, VIC, Australia

P26 Antibody responses to *P. falciparum* transmission-stage antigens in participants following a human experimental malaria infection study

Shirley Lu - Burnet Institute, and The Department of Medicine, University of Melbourne, Melbourne, VIC, Australia

P27 Evaluating the effects of sorbitol synchronization of clinical and laboratory isolates of *Plasmodium falciparum* on their susceptibility to antimalarial compounds

Frank Obeng Addae - Department of Biochemistry, Cell and

Molecular Biology, University of Ghana, Legon, Ghana



















Anti-malaria Synergy Team